XaMINA: A Real-World, Prospective, Observational Study of Treatment-Na ïve Patients Treated with Rivaroxaban for Stroke Prevention in Atrial Fibrillation in Asia

ConclusionXaMINA demonstrated low incidence rates of major bleeding events and thromboembolic events in patients with NVAF newly initiating rivaroxaban in South Korea and Taiwan, consistent with previous real-world studies reconfirming the results of the ROCKET AF study.Trial RegistrationThe trial was registered on ClinicalTrials.gov (identifier NCT03284762) on 15 September 2017.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research